Company / R&D Expense
TENAX THERAPEUTICS, INC. R&D Expense History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$12.7M
FY2025
5-year range
$2.5M / $12.7M
FY2021-FY2025
Trend
+293.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +294% YoY in FY2025, a notable deviation from the 6-year average annual change of +52%.
Based on SEC 10-K filings.
$13M in FY2025 with a 10-year CAGR of +15.5%.
Improved from $3M to $13M over the past 9 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +15.5%
Key checks
Key Insights
- In FY2025, r&d expense increased 293.6% year-over-year.
- Lowest r&d expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.7M | +293.6% |
| FY2024 | $3.2M | +7.8% |
| FY2016 | $3.0M | +0.0% |
| FY2015 | $3.0M | +22.0% |
| FY2014 | $2.5M | -0.3% |
| FY2013 | $2.5M | -8.2% |
| FY2012 | $2.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026